shengnuo biotechnology company Carbetocin Injection, the first generic product in China, passed the consistency evaluation

On the evening of September 6, shengnuo biotechnology company announced that its wholly-owned subsidiary Chengdu shengnuo biotechnology company has recently received the “Drug Supplementary Application Approval” for Carbetocin Injection approved and issued by the National Medical Products Administration. Notice”, the carbetocin injection developed by the company passed the quality and efficacy consistency evaluation of generic injection drugs.

The announcement shows that carbetocin injection is used in the obstetric field after elective epidural or spinal anesthesia caesarean section to prevent uterine atony and postpartum hemorrhage. It was launched in my country in 1984. Currently, carbetocin injection The liquid has entered my country’s Class B medical insurance directory. The carbetocin injection developed by shengnuo biotechnology company is the first generic product in China. In 2019, its domestic market share exceeded 20%, second only to the original product of Ferring Pharmaceuticals.

shengnuo biotechnology company Carbetocin Injection, the first generic product in China, passed the consistency evaluation stated that the carbetocin injection passed the quality and efficacy consistency evaluation of generic injection drugs, which is a reflection of the company’s comprehensive strength in R&D, production and quality management systems, and has accumulated experience for the company’s subsequent consistency evaluation product research. The rich experience will also help improve the market competitiveness of the product and have a positive impact on the company’s future operating performance.